Author

Alessandro Sinopoli

Primary ORCID profile (0000-0001-7993-4268 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Alessandro SinopoliiD1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Adel Atari· 1 shared Dennie Tompers FrederickiD· 1 shared Devishi KesariD· 1 shared Diego J. RodrigueziD· 1 shared Foxy P. RobinsoniD· 1 shared Jiwan KimiD· 1 shared Liang ChangiD· 1 shared Meilani Ching· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adel Atari

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Identification of potent biparatopic antibodies targeting FGFR2 fusion driven cholangiocarcinoma.

Saireudee Chaturantabut, Sydney Oliver, Dennie Tompers Frederick, Jiwan Kim, Foxy P. Robinson, Alessandro Sinopoli, Tianyu Song, Yao He, Y.H. Chang, Diego J. Rodriguez, Liang Chang, Devishi Kesar, Meilani Ching, Ruvimbo Dzvurumi, Adel Atari, , William R. Sellers

The paper identifies biparatopic antibodies targeting FGFR2 extracellular domain that effectively block FGFR2 fusion-driven cholangiocarcinoma signaling and growth.

Journal of Clinical Investigation · Feb 27, 2025Peer-reviewedCancer Biology